Applied NeuroSolutions Inc. (APNS) will receive $2 million up front in an early stage partnership with Eli Lilly and Co. focused on developing drugs targeting an underlying cause of Alzheimer's disease. (BioWorld Today)
Pulmatrix Inc. topped off its 2009 $30 million Series B with another $14 million to accelerate development of PUR118, its lead iCALM candidate, through Phase IIa studies in chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
